I attended a clinical research conference this week.
The presentations were not what stayed with me. What stayed with me were the conversations.
Again and again, I heard people talking about “getting treatments to patients”, “providing access to therapies”, and “matching patients to cutting-edge treatments”. These comments were not unusual. In fact, they were so commonplace that nobody seemed to notice them.
I did.
When I challenged the language, I was met largely with confusion.
Not hostility. Not disagreement. Confusion.
The distinction I was trying to make seemed obvious to me. A clinical trial is not a treatment. A clinical trial is research.
Yet the reaction made me wonder whether we have become so accustomed to certain phrases that we no longer hear what they imply.
This is not an argument against clinical trials.
Clinical trials are one of the most important tools we have for improving healthcare. They allow us to evaluate new interventions, challenge existing assumptions, and generate the evidence that ultimately improves patient care.
Nor is this an argument against translation, industry partnerships, innovation, or commercialisation. Translational research requires all of these things.
My concern is much simpler.
My concern is that we have started speaking as though uncertainty has already been resolved.
A patient receiving standard clinical care is being offered the best treatment currently known to be available.
A participant entering a clinical trial is being invited to participate in research designed to determine whether an intervention is safe, effective, superior, inferior, or perhaps no different from existing care.
Those are not the same thing.
The distinction is not semantic. It is the ethical foundation of clinical research.
If we already knew an intervention worked, there would often be little justification for randomising participants or conducting the trial in the first place. Clinical trials exist because the answer is unknown.
That uncertainty is not a flaw in the system.
It is the reason the system exists.
Yet throughout research culture we increasingly hear language suggesting otherwise. We speak about “getting treatments to patients”, “providing access to therapies”, and “matching patients to cutting-edge treatments”. Trial databases are searched so patients can access the latest treatment. Research participation is discussed as a treatment option.
The language sounds positive. Patient-centred. Optimistic.
The problem is that it is not necessarily accurate.
An investigational intervention is not a treatment simply because we hope it will become one.
A participant is not being matched to a proven therapy. They are being matched to a research protocol.
The difference matters.
Research ethics has spent decades attempting to minimise therapeutic misconception: the tendency for participants to confuse research with personalised clinical care. We carefully word participant information sheets. We avoid overstating potential benefits. We emphasise uncertainty. We explain that participation may or may not provide direct benefit.
Yet outside formal consent documents, the language often changes.
At conferences.
In strategic plans.
In funding announcements.
In policy discussions.
In casual conversations.
Suddenly research becomes treatment.
The irony is striking. We demand precision when speaking to participants, yet often abandon that same precision when speaking to one another.
Some may argue that this is simply shorthand.
Perhaps it is.
But language does more than communicate. Language establishes norms.
Junior researchers learn how to think from senior researchers.
Research nurses learn from investigators.
Students learn from supervisors.
Organisations learn from leaders.
When inaccurate language is repeated often enough, it becomes accepted. Once accepted, it becomes embedded in culture.
The issue is not that a single individual uses the wrong phrase.
The issue is institutional drift.
Over time, repeated references to “treatments”, “therapies”, and “access” subtly erode the distinction between research and care. The distinction remains in policy, ethics applications, and consent forms, but disappears from everyday conversation.
Eventually, people become confused when the distinction is pointed out.
That is what struck me most at the conference.
Not the language itself.
The reaction to questioning it.
The confusion suggested that many people no longer perceive a meaningful difference between participating in research and receiving treatment.
I believe that should concern us.
Not because anyone is acting in bad faith.
Not because clinical trials are harmful.
But because research depends upon honesty about uncertainty.
Participants volunteer for research precisely because the answer is not yet known. Their contribution is valuable because the outcome remains uncertain. A trial may demonstrate benefit. It may demonstrate no benefit. It may demonstrate harm. It may fail entirely.
That is not a weakness of research.
That is how research works.
Every unsuccessful trial reminds us of this reality. Interventions that appear promising can fail. Programs backed by compelling science can prove ineffective. Entire development pathways can be abandoned after years of investment.
Days before writing this piece, a major pharmaceutical company announced the termination of a Phase III trial following an interim futility analysis. There was no scandal. No misconduct. No regulatory failure. The trial simply failed to demonstrate the expected benefit. Such outcomes are common in clinical research and serve as an important reminder that investigational interventions are not treatments simply because they are promising. They are treatments only after the evidence demonstrates that they should become so.
This is not evidence that the system has failed.
It is evidence that the system is doing exactly what it was designed to do.
Research is not treatment.
It may lead to treatment.
It may identify better treatment.
It may reveal that a treatment does not work.
But until the question has been answered, we should be careful not to speak as though the answer is already known.
This is not political correctness.
It is not communications training.
It is not a request for softer language.
It is a request for intellectual and ethical consistency.
If we believe precision matters when speaking to participants, then precision should also matter when speaking to each other.
Because language shapes culture.
And culture shapes what future generations of researchers come to accept as true.
Further Reading
This essay draws on established concepts from research ethics including therapeutic misconception, clinical equipoise, informed consent, and the distinction between research and clinical care.
Appelbaum PS, Roth LH, Lidz CW. The Therapeutic Misconception (1982)
Freedman B. Equipoise and the Ethics of Clinical Research (1987)
NHMRC National Statement on Ethical Conduct in Human Research
UK Policy Framework for Health and Social Care Research
ICH E6(R3) Good Clinical Practice – Or take any Transcellerate approved Course I recommend face to face delivery